Rethinking the Science of Skin – The New Yorker

When my sister and I were young, we liked to come home from school and turn on Guiding Light, a soap opera on CBS. We only ever caught the last fifteen minutes of the hour-long show, but, because it wasnt particularly subtle, this was plenty of time to follow even its most involved plotlinessuch as when Reva Shayne, a nine-times-married character who had arcs as a talk-show host, a psychic, the princess of a fictional island, and a time traveller to the Civil War and Nazi Germany, had to fight Dolly, a devious clone that her most recent husband had made of her in order to spare her children from grief during the most recent of her presumed deaths.

Guiding Light began, in 1937, as a radio show to promote a soap called Duz. (Duz does everything.) When it went off the air, in 2009, it was the longest-running show in broadcast history. It was owned, until the end, not by CBS but by Procter & Gamble, which began as a soap company and has been credited with inventing modern advertising in America. In addition to promoting its brands with paintings on trolley cars and billboards, the company developed more than twenty radio and television dramas. The first, Oxydols Own Ma Perkins, premired in 1933; the last, As The World Turns, left the airwaves in 2010, by which time the term soap opera had become freestanding. You could even watch them, as I did, without ever knowing they had anything to do with a soap company.

It was easy, until the COVID-19 outbreak, not to think very often or very deeply about soap. Early in the pandemic, this began to change. We learned which pop songs had choruses that we could sing to keep us scrubbing for a full twenty seconds; we learned that, at least during the pre-lockdown period, the lines outside mens rooms grew suddenly longerlikely because (according to one study) only thirty-one per cent of men had previously been in the habit of washing their hands after using the bathroom. As distilleries and breweries pivoted to producing hand sanitizer, the Times ran a piece explaining why old-fashioned soap was actually better at destroying the coronavirus: the hydrophobic tails of soap molecules bond with the lipid membrane that protects the virus, literally ripping it apart, while their hydrophilic heads bond with the water that washes the dead virus away. Like many people, I developed a new appreciation for soap, imagining with grim satisfaction a scene of microscopic destruction each time I scrubbed my hands.

So this has been a strange time to be reading a book by a medical doctor which takes a critical view of the soap industry and begins with the sentence Five years ago, I stopped showering.

Let me clarify at once that James Hamblin, a staff writer at The Atlantic and the author of Clean: The New Science of Skin (Riverhead), is still an advocate of regular handwashing, indisputably a world-changing innovation in public health, and of especially crucial importance at this moment in history. (Hamblin also writes that he would never wear a white coat two days in a row without cleaning it.) But hes doubtful about all the scrubbing and soapingnot to mention moisturizing and deodorizing and serum-and-acid applicationto which we subject the rest of our bodys largest organ, and about the companies that spend a lot of money to convince us that we must do so to be clean.

Soap is an ancient invention, so old that we can only assume it was the lucky result of animal fat spilling into fire ash and some people being alert enough to notice the cleaning power of the resulting lather. Still, early versions, made with lye, could burn skin, and were used more often for laundry than for people. Bathing more commonly involved water, sand, pumice, scrapers, and oils or perfumesthough in certain places the whole notion was seen as dangerous. Some historical records suggest that washing was comparatively rare in the Western world: Marco Polo wrote of his surprise at how frequently people in India and China bathed, and Ahmad ibn Fadlan, who travelled from the court of Baghdad to the Volga River in the early tenth century, wrote that the people he met on his journey did not wash after eating, shitting, peeing, or having sex, and were the filthiest of Allahs creatures. The French historian Jules Michelet described the European Middle Ages as a thousand years without a bath.

In America, soap made for skin became commonly sold only in the nineteenth century, largely as a way to make money from the leftovers of the meatpacking industry, which produced large quantities of unused animal fat. Entrepreneurs added potash and made soap, for which they then needed to create public demand. These early soapers included William Procter and James Gamble, who began working together after marrying a pair of sisters; another familial pair, whose company name eventually changed from Lever Brothers to Unilever; and a man named William Wrigley, Jr., who gave away chewinggum as a promotion for his soap, but found that the gum was in higher demand.

Last year, the beauty-and-personal-care market in the U.S. was valued at nearly a hundred billion dollars, which makes it hard to imagine a time when people had to be persuaded to use soap. But the soap industry, Hamblin argues, serves as an effective introduction to the history of American marketing. Early soap companies pioneered many techniques that we still see today: a single company owning lots of competing brands with nearly identical products, in order to foster feelings of consumer choice and loyalty; the use of sponsored content, such as the soap operas or Procter & Gambles How to Bring Up a Baby, which was part health pamphlet and part advertisement. The ad campaigns created a sense of lurking danger in the competition by claiming that their own products were safer and purer, or they promoted, as product virtues, obscure, jargony terms (triple milled) that consumers assumed to be important simply because they were touted on a package. The companies leaned, not at all subtly, on racism and classism to sell their products. They even used people who would now be called influencers, such as the film stars who appeared in 9 out of 10 screen stars use Lux Toilet Soap ads. Lever never even paid them, Hamblin writes, and the practice being so new, the stars apparently didnt think to ask.

The other innovation was to create, and then meet, needs that people didnt know they had. Hamblin notes that B.O. began as a marketing term, and that many soaps advertised as antimicrobial and antibacterial were less safethan standard soap, leaving behind dangerous compounds. (Many products that we now think of as soaps are actually detergents, made from synthetic compounds.)

Meanwhile, soap companies, in order to expand their product lines, had to sell the idea that soap was insufficient on its ownor that its effects had to be undone by yet more products, Hamblin writes. You needed separate soaps for your hair, your body, your face, and even for different members of a family. (Albert Einstein, asked why he didnt use shaving cream, then newly invented, is reported to have replied, Two soaps? That is too complicated!) To offset the drying effects of soap, you then needed other productsconditioners, moisturizers, toners. Hamblin identifies the 1957 introduction of Dove, whose cleaning power is reduced because its mixed with moisturizer, as the moment when the industry started moving toward selling a product that would do nothing at all.

Follow this link:
Rethinking the Science of Skin - The New Yorker

Autologous Cell Therapy Market Research Outlook, Recent Trends and Growth Forecast 2020-2025 – Owned

The Autologous Cell Therapy report provides independent information about the Autologous Cell Therapy industry supported by extensive research on factors such as industry segments size & trends, inhibitors, dynamics, drivers, opportunities & challenges, environment & policy, cost overview, porters five force analysis, and key companies profiles including business overview and recent development.

Autologous Cell Therapy MarketLatest Research Report 2020:

Download Premium Sample Copy Of This Report: Download FREE Sample PDF!

In this report, our team offers a thorough investigation of Autologous Cell Therapy Market, SWOT examination of the most prominent players right now. Alongside an industrial chain, market measurements regarding revenue, sales, value, capacity, regional market examination, section insightful information, and market forecast are offered in the full investigation, and so forth.

Scope of Autologous Cell Therapy Market: Products in the Autologous Cell Therapy classification furnish clients with assets to get ready for tests, tests, and evaluations.

Major Company Profiles Covered in This Report

BioTime, Inc., BrainStorm Cell Therapeutics, Caladrius Biosciences, Inc., Fibrocell Science, Inc., Opexa Therapeutics, Inc., Pharmicell Co., Inc., Regeneus Ltd., TiGenix NV, TxCell SA, U.S. Stem Cell, Inc., Vericel Corporation

Autologous Cell Therapy Market Report Covers the Following Segments:

By Application: Neurology, Orthopedics, Cancer, Wound Healing, CVD, Autoimmune, Others

By Product: Bone Marrow, Epidermis

by Regional: Asia-Pacific, North America, Europe, South America, Middle East & Africa

North America

Europe

Asia-Pacific

South America

Center East and Africa

United States, Canada and Mexico

Germany, France, UK, Russia and Italy

China, Japan, Korea, India and Southeast Asia

Brazil, Argentina, Colombia

Saudi Arabia, UAE, Egypt, Nigeria and South Africa

Market Overview:The report begins with this section where product overview and highlights of product and application segments of the global Autologous Cell Therapy Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company:Here, the competition in the Worldwide Autologous Cell Therapy Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data:As the name suggests, this section gives the sales data of key players of the global Autologous Cell Therapy Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global Autologous Cell Therapy Market.

Market Status and Outlook by Region:In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Autologous Cell Therapy Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User:This section of the research study shows how different end-user/application segments contribute to the global Autologous Cell Therapy Market.

Market Forecast:Here, the report offers a complete forecast of the global Autologous Cell Therapy Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion:This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Top Trending Reports:

https://www.marketwatch.com/press-release/oil-country-tubular-goods-octg-market-size-2020-share-upcoming-trends-segmentation-and-forecast-to-2025-cagr-of-702-2020-04-24

https://www.marketwatch.com/press-release/oil-country-tubular-goods-octg-market-size-2020-share-upcoming-trends-segmentation-and-forecast-to-2025-cagr-of-702-2020-04-24

Top Trending Reports:

https://www.marketwatch.com/press-release/us-cystic-fibrosis-therapeutics-market-analysis-development-size-revenue-future-growth-business-prospects-and-forecast-2025-2020-07-22?tesla=y

https://www.marketwatch.com/press-release/europe-dental-surgical-equipment-market-size-by-2020-2025-manufacturers-advancements-sales-shares-challenges-opportunities-2020-07-22?tesla=y

https://www.marketwatch.com/press-release/us-vacuum-interrupter-market-overview-share-growth-upcoming-trends-segmentation-and-forecast-2020-2025-2020-07-21?tesla=y

https://www.marketwatch.com/press-release/europe-dental-surgical-equipment-market-size-by-2020-2025-manufacturers-advancements-sales-shares-challenges-opportunities-2020-07-22?tesla=y

https://www.marketwatch.com/press-release/europe-3d-ultrasound-bladder-scanners-market-industry-2020-top-countries-data-analysis-market-size-business-strategies-trends-and-forecast-2025-2020-07-22?tesla=y

Read the rest here:
Autologous Cell Therapy Market Research Outlook, Recent Trends and Growth Forecast 2020-2025 - Owned

Global Cell Therapy Technologies Market : Industry Analysis and Forecast (2019-2026) by Product, Technique, End Users and Region. – Red & Black…

Global Cell Therapy Technologies Market was valued US$ 12 billion in 2018 and is expected to reach US$ 35 billion by 2026, at CAGR of 12.14 %during forecast period.

The objective of the report is to present comprehensive assessment projections with a suitable set of assumptions and methodology. The report helps in understanding Global Cell Therapy Technologies Market dynamics, structure by identifying and analyzing the market segments and projecting the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, growth strategies, and regional presence. To understand the market dynamics and by region, the report has covered the PEST analysis by region and key economies across the globe, which are supposed to have an impact on market in forecast period. PORTERs analysis, and SVOR analysis of the market as well as detailed SWOT analysis of key players has been done to analyze their strategies. The report will to address all questions of shareholders to prioritize the efforts and investment in the near future to the emerging segment in the Global Cell Therapy Technologies Market.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Global Cell Therapy Technologies Market: Overview

Cell therapy is a transplantation of live human cells to replace or repair damaged tissue and/or cells. With the help of new technologies, limitless imagination, and innovative products, many different types of cells may be used as part of a therapy or treatment for different types of diseases and conditions. Celltherapy technologies plays key role in the practice of medicine such as old fashioned bone marrow transplants is replaced by Hematopoietic stem cell transplantation, capacity of cells in drug discovery. Cell therapy overlap with different therapies like, gene therapy, tissue engineering, cancer vaccines, regenerative medicine, and drug delivery. Establishment of cell banking facilities and production, storage, and characterization of cells are increasing volumetric capabilities of the cell therapy market globally. Initiation of constructive guidelines for cell therapy manufacturing and proven effectiveness of products, these are primary growth stimulants of the market.

REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/31531

Global Cell Therapy Technologies Market: Drivers and Restraints

The growth of cell therapy technologies market is highly driven by, increasing demand for clinical trials on oncology-oriented cell-based therapy, demand for advanced cell therapy instruments is increasing, owing to its affordability and sustainability, government and private organization , investing more funds in cell-based research therapy for life-style diseases such as diabetes, decrease in prices of stem cell therapies are leading to increased tendency of buyers towards cell therapy, existing companies are collaborating with research institute in order to best fit into regulatory model for cell therapies.Moreover, Healthcare practitioners uses stem cells obtained from bone marrow or blood for treatment of patients with cancer, blood disorders, and immune-related disorders and Development in cell banking facilities and resultant expansion of production, storage, and characterization of cells, these factors will drive the market of cell therapy technologies during forecast period.

On the other hand, the high cost of cell-based research and some ethical issue & legally controversial, are expected to hamper market growth of Cell Therapy Technologies during the forecast period

AJune 2016, there were around 351 companies across the U.S. that were engaged in advertising unauthorized stem cell treatments at their clinics. Such clinics boosted the revenue in this market. in August 2017, the U.S. FDA announced increased enforcement of regulations and oversight of clinics involved in practicing unapproved stem cell therapies. This might hamper the revenue generation during the forecast period; nevertheless, it will allow safe and effective use of stem cell therapies.

Global Cell Therapy Technologies Market: Segmentation Analysis

On the basis of product, the consumables segment had largest market share in 2018 and is expected to drive the cell therapy instruments market during forecast period at XX % CAGR owing to the huge demand for consumables in cell-based experiments and cancer research and increasing number of new product launches and consumables are essential for every step of cell processing. This is further expected to drive their adoption in the market. These factors will boost the market of Cell Therapy Technologies Market in upcoming years.

On the basis of process, the cell processing had largest market share in 2018 and is expected to grow at the highest CAGR during the forecast period owing to in cell processing stage,a use of cell therapy instruments and media at highest rate, mainly in culture media processing. This is a major factor will drive the market share during forecast period.

Global Cell Therapy Technologies Market: Regional Analysis

North America to held largest market share of the cell therapy technologies in 2018 and expected to grow at highest CAGR during forecast period owing to increasing R&D programs in the pharmaceutical and biotechnology industries. North America followed by Europe, Asia Pacific and Rest of the world (Row).

DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/31531

Scope of Global Cell Therapy Technologies Market

Global Cell Therapy Technologies Market, by Product

Consumables Equipment Systems & Software Global Cell Therapy Technologies Market, by Cell Type

Human Cells Animal Cells Global Cell Therapy Technologies Market, by Process Stages

Cell Processing Cell Preservation, Distribution, and Handling Process Monitoring and Quality Control Global Cell Therapy Technologies Market, by End Users

Life Science Research Companies Research Institutes Global Cell Therapy Technologies Market, by Region

North America Europe Asia Pacific Middle East & Africa South America Key players operating in the Global Cell Therapy Technologies Market

Beckman Coulter, Inc. Becton Dickinson and Company GE Healthcare Lonza Merck KGaA MiltenyiBiotec STEMCELL Technologies, Inc. Terumo BCT, Inc. Thermo Fisher Scientific, Inc. Sartorius AG

MAJOR TOC OF THE REPORT

Chapter One: Cell Therapy Technologies Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Cell Therapy Technologies Market Competition, by Players

Chapter Four: Global Cell Therapy Technologies Market Size by Regions

Chapter Five: North America Cell Therapy Technologies Revenue by Countries

Chapter Six: Europe Cell Therapy Technologies Revenue by Countries

Chapter Seven: Asia-Pacific Cell Therapy Technologies Revenue by Countries

Chapter Eight: South America Cell Therapy Technologies Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Cell Therapy Technologies by Countries

Chapter Ten: Global Cell Therapy Technologies Market Segment by Type

Chapter Eleven: Global Cell Therapy Technologies Market Segment by Application

Chapter Twelve: Global Cell Therapy Technologies Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Cell Therapy Technologies Market Report at: https://www.maximizemarketresearch.com/market-report/global-cell-therapy-technologies-market/31531/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Visit link:
Global Cell Therapy Technologies Market : Industry Analysis and Forecast (2019-2026) by Product, Technique, End Users and Region. - Red & Black...

Team led by Manchester Scientists discover a way to slow the growth of breast cancer stem cells – About Manchester – About Manchester

A team of British and American scientists have discovered a way to slow the growth of breast cancer stem cells in the lab.

The study led by Dr Bruno Simes and Professor Rob Clarke from The University of Manchester could eventually lead to combination drug therapies on previously untreatable breast cancers.

Around three quarters of women who have breast cancer have what are known as oestrogen receptor positive tumours.

Some breast cancer cells have receptors that bind to the hormone oestrogen and depend on it to grow.

Though anti-oestrogen drugs such as tamoxifen and fulvestrant are able to prevent reoccurrence in most of these breast cancers, tumours reoccur in 1 out of 4 cases.

Many of the women relapse after several years, because some of the cancer cells remain after treatment.

The cells, called cancer stem cells, lay dormant in the body and cannot be targeted by anti-oestrogen therapies.

Scientists have now found that cancer stem cells resistant to anti-oestrogen drugs express an immune system-related receptor called interleukin 1 receptor.

The team found that a biological inhibitor of this receptor called Anakinra, used to treat rheumatoid arthritis, was able to reduce the ability of the cancer stem cells to form colonies in vitro.

However, further validation in animals and humans is required before the team to confirm if drugs targeting interleukin 1 receptor could be used as an effective treatment.

The study, published in Stem Cell Reports was funded by the Medical Research Council and Breast Cancer Now.

Scientists from the Universities of Michigan, Liverpool and Edinburgh were closely involved in the work from the team in Manchester.

Dr Simes said: Resistance to anti-oestrogen therapies in breast cancer patients is a major problem and one which cancer scientists have been trying to address for many years.

Many drugs have been investigated by scientists as a possible combination therapy taken with anti-oestrogen therapies and we are still searching for a solution for these patients.

However, most of these drugs target actively dividing cells whereas we are trying to also target cells that are in a dormant state.

So we hope that these women who have increased numbers of cancer stem cells and do not respond to currents treatment could one day benefit from combination therapy.

Theres a very long way to go before we can say if this approach will help these women but we are excited by our findings.

Continue reading here:
Team led by Manchester Scientists discover a way to slow the growth of breast cancer stem cells - About Manchester - About Manchester

Boehringer Ingelheim acquires GST to strengthen its stem cell capabilities in Animal Health – Business Wire

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim, a market leader in animal health, has acquired Global Stem cell Technology (GST), a Belgian veterinary biotech company. GST is dedicated to the research, development and production of evidence-based, regenerative medicines (stem cell therapies) used to treat orthopedic and metabolic diseases in animals. Boehringer Ingelheim already entered into a partnership with GST in 2018; in 2019, the companies launched Arti-Cell Forte in Europe.

Arti-Cell Forte is testimony to the innovation strength that lies within both companies. It is the first-ever stem cell product in the veterinary world granted marketing authorization by the European Commission. The acquisition and integration of GST will accelerate the development pipeline of Boehringer Ingelheim while maintaining its focus on setting new standards of care for animals.

Collaboration with external partners plays an essential role in helping us expand our portfolio. After two years of a very successful partnership, we have decided to acquire GST. We are convinced that its expertise in the field of state-of-the art stem cell products will help us bring even more innovative solutions to our customers, shares Jean-Luc Michel, Head of Global Strategic Marketing, Boehringer Ingelheim Animal Health.

Boehringer Ingelheim wants to lead a new wave of innovation in the veterinary field. This ambition is a natural fit with GSTs management, staff and vision. From the very beginning we aimed to change the veterinary field, a role we will continue to play as a new R&D division within Boehringer Ingelheim, says Jan Spaas, CEO of GST.

This decision is fully aligned with our recently refocused strategic direction. Stem cell research areas and regenerative medicine offer an exciting potential for the next wave of innovation we are actively pursuing. In addition, strengthening external partnerships to accelerate our innovative efforts and growth is one of the key elements of our strategy, adds Eric Haaksma, Head of Global Innovation at Boehringer Ingelheim Animal Health.

The companies did not disclose the financial terms of the deal.

For references and notes to editors, please visit:

http://www.boehringer-ingelheim.com/press-release/boehringer-ingelheim-acquires-global-stem-cell-technology

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

See the original post:
Boehringer Ingelheim acquires GST to strengthen its stem cell capabilities in Animal Health - Business Wire

Cell Therapy Market Size, Opportunities And Forecast Analysis To 2026| Gilead Sciences, Novartis, Osiris – Owned

QY Research has Published Latest Trending Report on Global Cell Therapy Market

Los Angeles, United State, The report titledGlobal Cell Therapy Marketis one of the most comprehensive and important additions to QY Researchs archive of market research studies. It offers detailed research and analysis of key aspects of the global Cell Therapy market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Cell Therapy market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global Cell Therapy market is carefully analyzed and researched about by the market analysts.

Request Sample Report and Full Report TOC:https://www.qyresearch.com/sample-form/form/1555639/global-cell-therapy-market

The Essential Content Covered in the GlobalCell Therapy Market Report:

* Top Key Company Profiles. * Main Business and Rival Information * SWOT Analysis and PESTEL Analysis * Production, Sales, Revenue, Price and Gross Margin * Market Share and Size

Global Cell Therapy Market is estimated to reach xxx million USD in 2020 and projected to grow at the CAGR of xx% during 2020-2026. According to the latest report added to the online repository of QY Research the Cell Therapy market has witnessed an unprecedented growth till 2020. The extrapolated future growth is expected to continue at higher rates by 2025.

Top Players of Cell Therapy Market are Studied: , Gilead Sciences, Novartis, Osiris, Vericel Corporation, Vcanbio, Fujifilm Cellular Dynamics, JCR Pharmaceuticals, Beike Biotechnology, Golden Meditech, Guanhao Biotech

The report provides a 6-year forecast (2020-2026) assessed based on how the Cell Therapy market is predicted to grow in major regions likeUSA, Europe, Japan, China, India, Southeast Asia, South America, South Africa, Others.

Segmentation by Type:, Stem Cell, Non-Stem Cell

Segmentation by Application: Hospital, Clinic

Reasons to Buy this Report:

Table of Contents

1 Market Overview of Cell Therapy 1.1 Cell Therapy Market Overview 1.1.1 Cell Therapy Product Scope 1.1.2 Market Status and Outlook 1.2 Global Cell Therapy Market Size Overview by Region 2015 VS 2020 VS 2026 1.3 Global Cell Therapy Market Size by Region (2015-2026) 1.4 Global Cell Therapy Historic Market Size by Region (2015-2020) 1.5 Global Cell Therapy Market Size Forecast by Region (2021-2026) 1.6 Key Regions, Cell Therapy Market Size YoY Growth (2015-2026) 1.6.1 North America Cell Therapy Market Size YoY Growth (2015-2026) 1.6.2 Europe Cell Therapy Market Size YoY Growth (2015-2026) 1.6.3 Asia-Pacific Cell Therapy Market Size YoY Growth (2015-2026) 1.6.4 Latin America Cell Therapy Market Size YoY Growth (2015-2026) 1.6.5 Middle East & Africa Cell Therapy Market Size YoY Growth (2015-2026) 2 Cell Therapy Market Overview by Type 2.1 Global Cell Therapy Market Size by Type: 2015 VS 2020 VS 2026 2.2 Global Cell Therapy Historic Market Size by Type (2015-2020) 2.3 Global Cell Therapy Forecasted Market Size by Type (2021-2026) 2.4 Stem Cell 2.5 Non-Stem Cell 3 Cell Therapy Market Overview by Application 3.1 Global Cell Therapy Market Size by Application: 2015 VS 2020 VS 2026 3.2 Global Cell Therapy Historic Market Size by Application (2015-2020) 3.3 Global Cell Therapy Forecasted Market Size by Application (2021-2026) 3.4 Hospital 3.5 Clinic 4 Global Cell Therapy Competition Analysis by Players 4.1 Global Cell Therapy Market Size (Million US$) by Players (2015-2020) 4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cell Therapy as of 2019) 4.3 Date of Key Manufacturers Enter into Cell Therapy Market 4.4 Global Top Players Cell Therapy Headquarters and Area Served 4.5 Key Players Cell Therapy Product Solution and Service 4.6 Competitive Status 4.6.1 Cell Therapy Market Concentration Rate 4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data 5.1 Gilead Sciences 5.1.1 Gilead Sciences Profile 5.1.2 Gilead Sciences Main Business 5.1.3 Gilead Sciences Products, Services and Solutions 5.1.4 Gilead Sciences Revenue (US$ Million) & (2015-2020) 5.1.5 Gilead Sciences Recent Developments 5.2 Novartis 5.2.1 Novartis Profile 5.2.2 Novartis Main Business and Companys Total Revenue 5.2.3 Novartis Products, Services and Solutions 5.2.4 Novartis Revenue (US$ Million) (2015-2020) 5.2.5 Novartis Recent Development and Reaction to Covid-19 5.3 Osiris 5.5.1 Osiris Profile 5.3.2 Osiris Main Business 5.3.3 Osiris Products, Services and Solutions 5.3.4 Osiris Revenue (US$ Million) & (2015-2020) 5.3.5 Vericel Corporation Recent Developments 5.4 Vericel Corporation 5.4.1 Vericel Corporation Profile 5.4.2 Vericel Corporation Main Business 5.4.3 Vericel Corporation Products, Services and Solutions 5.4.4 Vericel Corporation Revenue (US$ Million) & (2015-2020) 5.4.5 Vericel Corporation Recent Developments 5.5 Vcanbio 5.5.1 Vcanbio Profile 5.5.2 Vcanbio Main Business 5.5.3 Vcanbio Products, Services and Solutions 5.5.4 Vcanbio Revenue (US$ Million) & (2015-2020) 5.5.5 Vcanbio Recent Developments 5.6 Fujifilm Cellular Dynamics 5.6.1 Fujifilm Cellular Dynamics Profile 5.6.2 Fujifilm Cellular Dynamics Main Business 5.6.3 Fujifilm Cellular Dynamics Products, Services and Solutions 5.6.4 Fujifilm Cellular Dynamics Revenue (US$ Million) & (2015-2020) 5.6.5 Fujifilm Cellular Dynamics Recent Developments 5.7 JCR Pharmaceuticals 5.7.1 JCR Pharmaceuticals Profile 5.7.2 JCR Pharmaceuticals Main Business and Companys Total Revenue 5.7.3 JCR Pharmaceuticals Products, Services and Solutions 5.7.4 JCR Pharmaceuticals Revenue (US$ Million) (2015-2020) 5.7.5 JCR Pharmaceuticals Recent Development and Reaction to Covid-19 5.8 Beike Biotechnology 5.8.1 Beike Biotechnology Profile 5.8.2 Beike Biotechnology Main Business 5.8.3 Beike Biotechnology Products, Services and Solutions 5.8.4 Beike Biotechnology Revenue (US$ Million) & (2015-2020) 5.8.5 Beike Biotechnology Recent Developments 5.9 Golden Meditech 5.9.1 Golden Meditech Profile 5.9.2 Golden Meditech Main Business 5.9.3 Golden Meditech Products, Services and Solutions 5.9.4 Golden Meditech Revenue (US$ Million) & (2015-2020) 5.9.5 Golden Meditech Recent Developments 5.10 Guanhao Biotech 5.10.1 Guanhao Biotech Profile 5.10.2 Guanhao Biotech Main Business 5.10.3 Guanhao Biotech Products, Services and Solutions 5.10.4 Guanhao Biotech Revenue (US$ Million) & (2015-2020) 5.10.5 Guanhao Biotech Recent Developments 6 North America 6.1 North America Cell Therapy Market Size by Country 6.2 United States 6.3 Canada 7 Europe 7.1 Europe Cell Therapy Market Size by Country 7.2 Germany 7.3 France 7.4 U.K. 7.5 Italy 7.6 Russia 7.7 Nordic 7.8 Rest of Europe 8 Asia-Pacific 8.1 Asia-Pacific Cell Therapy Market Size by Region 8.2 China 8.3 Japan 8.4 South Korea 8.5 Southeast Asia 8.6 India 8.7 Australia 8.8 Rest of Asia-Pacific 9 Latin America 9.1 Latin America Cell Therapy Market Size by Country 9.2 Mexico 9.3 Brazil 9.4 Rest of Latin America 10 Middle East & Africa 10.1 Middle East & Africa Cell Therapy Market Size by Country 10.2 Turkey 10.3 Saudi Arabia 10.4 UAE 10.5 Rest of Middle East & Africa 11 Cell Therapy Market Dynamics 11.1 Industry Trends 11.2 Market Drivers 11.3 Market Challenges 11.4 Market Restraints 12 Research Finding /Conclusion 13 Methodology and Data Source 13.1 Methodology/Research Approach 13.1.1 Research Programs/Design 13.1.2 Market Size Estimation 13.1.3 Market Breakdown and Data Triangulation 13.2 Data Source 13.2.1 Secondary Sources 13.2.2 Primary Sources 13.3 Disclaimer 13.4 Author List

About US

QY Research is a leading global market research and consulting company. Established in 2007 in Beijing, China, QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and custom research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services.

Continued here:
Cell Therapy Market Size, Opportunities And Forecast Analysis To 2026| Gilead Sciences, Novartis, Osiris - Owned

"Self-eating" Process of Stem Cells May be Key to New Regenerative Therapies – Mirage News

Translucently colored embryonic stem (ES) cell (upper right) and its differentiating derivatives (left and lower right). The small round bodies inside cells represent lysosomes, with the pink color indicating ones that are undergoing chaperone-mediated autophagy (CMA), a selective form of autophagy that is demonstrated only in mammals. CMA governs the balance between self-renewal and differentiation of ES cells. It is kept at low levels in undifferentiated ES cells to maintain the pluripotent state. Upon induction of differentiation, CMA flux increases due to the reduction of pluripotency factors, leading to changes in cellular metabolism and epigenetic landscape that favor differentiation.

PHILADELPHIAThe self-eating process in embryonic stem cells known as chaperone-mediated autophagy (CMA) and a related metabolite may serve as promising new therapeutic targets to repair or regenerate damaged cells and organs, Penn Medicine researchers show in a new study published online in Science.

Human bodies contain over 200 different types of specialized cells. All of them can be derived from embryonic stem (ES) cells, which relentlessly self-renew while retaining the ability to differentiate into any cell type in adult animals, a state known as pluripotency. Researchers have known that the cells metabolism plays a role in this process; however, it wasnt clear exactly how the cells internal wiring works to keep that state and ultimately decide stem cell fate.

The new preclinical study, for the first time, shows how the stem cells keeps CMA at low levels to promote that self-renewal, and when the stem cell is ready, it switches that suppression off to enhance CMA, among other activities, and differentiate into specialized cells.

Its an intriguing discovery in the field of stem cell biology and for researchers looking to develop therapies for tissue or organ regeneration, said senior author Xiaolu Yang, PhD, a professor of Cancer Biology at the Abramson Family Cancer Research Institute in the Perelman School of Medicine at the University of Pennsylvania. We reveal two novel ways to potentially manipulate the self-renewal and differentiation of stem cells: CMA and a metabolite, known as alpha-ketoglutarate, that is regulated by CMA. Rationally intervening or guiding these functions could be a powerful way to increase the efficiency of regenerative medicine approaches.

Autophagy is a cell-eating mechanism necessary for survival and function of most living organisms. When cells self-eat, the intracellular materials are delivered to lysosomes, which are organelles that help break down these materials. There are a few forms of autophagy. However, unlike the other forms, which are present in all eukaryotic cells, CMA is unique to mammals. To date, the physiological role of CMA remains unclear.

Using metabolomic and genetic laboratory techniques on the embryonic stem cells of mice, the researchers sought to better understand significant changes that took place during their pluripotent state and subsequent differentiation.

They found that CMA activity is kept at a minimum due to two cellular factors critical for pluripotencyOct4 and Sox2that suppresses a gene known as LAMP2A, which provides instructions for making a protein called lysosomal associated membrane protein-2 necessary in CMA. The minimal CMA activity allows stem cells to maintain high levels of alpha-ketoglutarate, a metabolite that is crucial to reinforce a cells pluripotent state, the researchers found.

When its time for differentiation, the cells begin to upregulate CMA due to the reduction in Oct4 and Sox2. Augmented CMA activity leads to the degradation of key enzymes responsible for the production of alpha-ketoglutarate. This leads to a reduction in alpha-ketoglutarate levels as well as an increases in other cellular activities to promote differentiation. These findings reveal that CMA and alpha-ketoglutarate dictate the fate of embryonic stem cells.

Embryonic stem cells are often called pluripotent due to their remarkable ability to give rise to every cell type in the body, except the placenta and umbilical cord. Embryonic stem cells not only provide a superb system to study early mammalian development, but also hold great promise for regenerative therapies to treat various human disorders. The development of stem-cell based regenerative medicine therapies has rapidly increased in the last decade, with several approaches in studies shown to repair damaged heart tissue, replace cells in solid organ transplantation, and in some cases address neurological disorders.

This newly discovered role of autophagy in the stem cell is the beginning of further investigations that could lead to researchers and physician-scientists to better therapies to treat various disorders, Yang said.

Penn co-authors of the study include the first author Yi Xu, a post-doctoral researcher in Yangs Lab, Yang Zhang and Sixiang Yu, also in Yangs lab, Lili Guo and Ian A. Blair of the department of Systems Pharmacology and Translational Therapeutics, Mengyuan Kan of the department of Biostatistics, Epidemiology and Informatics, as well as Juan C. Garca-Caaveras and Joshua D. Rabinowitz of Princeton University.

The study was supported the National Institutes of Health (R01CA182675, R01CA184867, R01CA235760, and P30ES013508, and the Department of Defense (W81XWH-15-1-0678).

View post:
"Self-eating" Process of Stem Cells May be Key to New Regenerative Therapies - Mirage News

R3 International Offering New Program for Stem Cell Therapy for Back Pain in Mexico – Yahoo Finance

The leading stem cell treatment center in Mexico, R3 International, is now offering a new program for stem cell therapy for back pain. The treatments include 30 million stem cells up to 200 million, and start at only $2975.

SCOTTSDALE, Ariz., July 27, 2020 /PRNewswire-PRWeb/ -- The leading stem cell treatment center in Mexico, R3 International, is now offering a new program for stem cell therapy for back pain. The treatments include 30 million stem cells up to 200 million, and start at only $2975.

With close to 9 out of 10 experiencing significant back pain at some point in life, there are millions of individuals who deal with back pain every day. It may be incapacitating, with traditional treatment options often not working exceptionally well. This may include risky narcotics or surgery.

According to R3 CEO David Greene, MD, MBA, "Chronic back pain dampens quality of life, with patients often not being able to work or play with their kids or grandkids. Stem cell treatment with R3 in Mexico is a fantastically effective option for those who want to eliminate pain without surgery or narcotics. It starts at only $2975 too!"

Stem cell therapy for back pain in Mexico at R3 International provides a safe, effective option for patients to alleviate back pain without surgery. Depending on the patient's reason for back pain, treatment may be provided IV, injection, intrathecal or with a combination. Each individual undergoes a free consultation with one of R3's licensed, experienced stem cell doctors who will review medical records and make the treatment suggestion.

Patient satisfaction at R3 Stem Cell International exceeds 87% overall, with treatments being offered for back pain, joint arthritis, Lyme disease, kidney failure, COPD, stroke, neuropathy, Alzheimers, diabetes, Crohns and more. Patients receive an escort from San Diego to the Tijuana clinic, which is only 20 minutes away along with an escort to the treatment and back.

To get set up for a free phone consultation, call (888) 988-0515 and visit https://stemcelltreatmentclinic.com for more information.

SOURCE R3 Stem Cell International

Read the original:
R3 International Offering New Program for Stem Cell Therapy for Back Pain in Mexico - Yahoo Finance

Autologous Stem Cell and Non-Stem Cell Based Therapies Market To Grow at a Stayed CAGR from 2019 to 2026 – Owned

Data Bridge Market research has published yet another new report thoroughly explains each and every aspect related to the Autologous Stem Cell and Non-Stem Cell Based Therapies market. This report can help the user to better understand the opportunities and threats that are doled by the industry and its players. The different areas covered in the report are Global Autologous Stem Cell and Non-Stem Cell Based Therapies market size, drivers and restraints, segment analysis, geographic outlook, major manufacturers in the market, competitive landscape, value/volume data, marketing strategies, and expert views.

Get Free Full PDF Sample Copy of Report + Full TOC, List of Tables, Figures & Chart at: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market

The Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market research report assembles data collected from different regulatory organizations to assess the growth of the segments. In addition, the study also appraises the global Autologous Stem Cell and Non-Stem Cell Based Therapies market on the basis of topography. It reviews the macro- and microeconomic features influencing the growth of the Autologous Stem Cell and Non-Stem Cell Based Therapies Market in each region. Various methodological tools are used to analyze the growth of the worldwide Autologous Stem Cell and Non-Stem Cell Based Therapies market.

List of Companies Profiled in the Autologous Stem Cell and Non-Stem Cell Based Therapies Market Report are:

Takeda Pharmaceutical Company Limited, Cytori Therapeutics Inc., General Electric Spiegelberg GmbH & Co. KG ., Medtronic, Natus Medical Incorporated., Integra LifeSciences Corporation, RAUMEDIC AG, Abbott., Endotronix, Inc. among others.

Major Regions as Follows:

North America

Europe

Asia-Pacific

South America

Middle East and Africa

Key Answers Captured in Autologous Stem Cell and Non-Stem Cell Based Therapies Objectives are:

Key Important Pointers Covered in the Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Trendsand Forecast to 2026

A complete value chain of the global Autologous Stem Cell and Non-Stem Cell Based Therapies market is presented in the research report. It is associated with the review of the downstream and upstream components of the Autologous Stem Cell and Non-Stem Cell Based Therapies Market. The market is spliton the basis of the categories of products and clientapplication segments. The market analysis demonstrates the expansion of each segment of the global Autologous Stem Cell and Non-Stem Cell Based Therapies market. The research report assists the user in taking a decisive step on the way tobe a milestone ingrowingandexpandingtheirorganizationsinside theworldwideAutologous Stem Cell and Non-Stem Cell Based Therapies market.

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart):https://www.databridgemarketresearch.com/toc/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market

The report highlights current and future market trends and carries out an analysis of the effect of buyers, substitutes, new entrants, competitors, and suppliers on the market. The key topics that have been explained in this Autologous Stem Cell and Non-Stem Cell Based Therapies market report include market definition, market segmentation, key developments, competitive analysis and research methodology.

The key highlights of this report

TABLE OF CONTENTS

Part 01:Executive Summary

Part 02:Scope of the Report

Part 03:Research Methodology

Part 04:Market Landscape

Part 05:Pipeline Analysis

Part 06:Market Sizing

Market Definition

Market Sizing

Market Size And Forecast

Part 07:Five Forces Analysis

Bargaining Power Of Buyers

Bargaining Power Of Suppliers

Threat Of New Entrants

Threat Of Substitutes

Threat Of Rivalry

Market Condition

Part 08:Market Segmentation

Segmentation

Comparison

Market Opportunity

Part 09:Customer Landscape

Part 10:Regional Landscape

Part 11:Decision Framework

Part 12:Drivers and Challenges

Part 13:Market Trends

Part 14:Vendor Landscape

Part 15:Vendor Analysis

Vendors Covered

Vendor Classification

Market Positioning Of Vendors

Part 16:Appendix

In conclusion, the Autologous Stem Cell and Non-Stem Cell Based Therapies Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report Give information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis is also incorporated in the report along with speculation attainability inspection and venture return investigation.

To Get the Short-Term and Long-Term Impact of COVID-19 on this Market:https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Customization of the Report:

Data Bridge Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

See the original post here:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market To Grow at a Stayed CAGR from 2019 to 2026 - Owned

Cell Therapy Instrument Market IN COVID-19: IMPLICATIONS AND BUSINESS OPPORTUNITIES FOR GROWTH GLOBALLY – Owned

The Cell Therapy Instrument Market report has been recently added by Report Ocean to its vast repository. This intelligence report includes investigations based on Historical records, Current scenarios, and future predictions. It presents the 360-degree overview of the competitive landscape of the industries. SWOT analysis has been used to understand the Strength, Weaknesses, Opportunities, and threats in front of the businesses. Cell Therapy Instrument Market is showing steady growth and CAGR is expected to improve during the forecast period.

The Cell Therapy Instrument Market Research Report categorizes the Cell Therapy Instrument Market by key players, product type, applications, and regions, etc. The report also covers the latest industry data, key players analysis, market share, growth rate, opportunities and trends, investment strategy for your reference in analyzing the Cell Therapy Instrument Market.

COVID- 19 Impact on Cell Therapy Instrument Market

As companies move from reacting to mitigating the impact of the COVID-19 outbreak, they are keenly focusing on strategies that may result in emerging as strong market player. This market research report included the detailed study related to impact of COVID-19 on the supply chain based on both downstream and upstream markets. The report also includes the future development in the Cell Therapy Instrument Market in relation with the impact of COVID-19 on the market.

Request Free Sample Report athttps://www.reportocean.com/industry-verticals/sample-request?report_id=bis64080

Competitive Landscape:

This section of the report has mainly focused on Key Strategies adopted by leading players in Cell Therapy Instrument Market. These companies are selected based on revenue, innovations, strength of product portfolio, regional presence, investment capacity and similar other factors.

BD Bioscience Danaher (Beckman Coulter, Inc.) General Electric Lonza Merck Kgaa Miltenyi Biotec Sartorius AG Stemcell Technologies Inc. Terumo Corporation Thermo Fisher Scientific Inc.

Market Segmentation:

The segmentation is used to decide the target market into smaller sections or segments like product type, application, and geographical regions to optimize marketing strategies, advertising technique and global as well as regional sales efforts of Cell Therapy Instrument Market.

Product Type Segmentation Human Cells Animal Cells

Industry Segmentation Cell Processing Cell Preservation Distribution & Handling Process Monitoring & Quality Control

Channel (Direct Sales, Distributor) Segmentation

Region Segmentation:

Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in Cell Therapy Instrument Market. The regional analysis section of the report offers an extensive analysis of the Cell Therapy Instrument Market based on region. The Cell Therapy Instrument Market will showcase a steady CAGR in the forecast year.

Unravelling the geographical landscape of the Cell Therapy Instrument Market:

Americas (United States, Canada, Mexico, Brazil)

APAC (China, Japan, Korea, Southeast Asia, India, Australia)

Europe (Germany, France, UK, Italy, Russia, Spain)

Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries)

Some of the Points cover in Cell Therapy Instrument Market Research Report are:

Chapter 1: Overview of Cell Therapy Instrument Market

Definition

Specifications

Classification

Applications

Regions

Chapter 2: Market Competition by Players/Suppliers

Manufacturing Cost Structure

Raw Material and Suppliers

Manufacturing Process

Industry Chain Structure

Chapter 3: Sales (Volume) and Revenue (Value) by Region

Sales

Revenue and market share

Chapter 4, 5 and 6: Cell Therapy Instrument Market by Type, Application & Players/Suppliers Profiles

Market Share by Type & Application

Growth Rate by Type & Application

Drivers and Opportunities

Company Basic Information

Continued

Note: Regional Breakdown & Sectional purchase Available We provide Pie chats Best Customize Reports As per Requirements.

For more information and discount on this report, ask your query at:https://www.reportocean.com/industry-verticals/sample-request?report_id=bis64080

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe, and Asia.

Contact Us: +1 888 212 3539 (US) +91-9997112116 (Outside US) Contact Person: Tom Email:[emailprotected]

Link:
Cell Therapy Instrument Market IN COVID-19: IMPLICATIONS AND BUSINESS OPPORTUNITIES FOR GROWTH GLOBALLY - Owned